A Phase 3 interventional study of Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg and Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg in Hypertension, sponsored by George Medicines PTY Limited. Completed at 47 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by George Medicines PTY Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 18th largest by enrollment, is one of 3 that started in 2021, is one of 40 in phase 3, and was the 89th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 755 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
George Medicines PTY Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.
George Medicines PTY Limited has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to placebo.
TRIAL DRUG:
GMRx2: single pill combination of telmisartan/amlodipine/indapamide Dose version 1: telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg Dose version 2: telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg INDICATION: Hypertension
TRIAL TITLE:
Efficacy and safety of GMRx2 compared to placebo for the treatment of hypertension.
OBJECTIVES:
To investigate the efficacy and safety of GMRx2 compared to placebo for the treatment of hypertension.
INTERVENTION:
A 2-week single-blind placebo run-in will be followed by a 4-week double-blind period with randomization to GMRx2 dose version 1, GMRx2 dose version 2 or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At screening visit:
Likely diagnosis of hypertension, defined as one or more of:
At randomization visit:
Exclusion Criteria:
At screening visit:
At randomization visit:
Any of the following which in the investigator's judgment may compromise the safety of the participant if randomized to the trial medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
Drug: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
Placebo
Drug: Placebo
Drug page: Telmisartan
Oral tablets
Drug page: Telmisartan
Oral tablets
Placebo
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\>60 mmHg and \<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.
Time frame: Randomization to Week 4
Difference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\>60 mmHg and \<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.
Time frame: Randomization to Week 4
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4
Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\>40mmHg and \<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.
Time frame: Randomization to Week 4
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4
The percentage of participants achieving averaged clinic SBP \<140 and DBP \<90 mmHg at Week 4 was evaluated.
Time frame: At Week 4
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4
The percentage of participants achieving averaged clinic SBP \<130 and DBP \<80 mmHg at Week 4 was evaluated. Participants were analyzed in the treatment group to which they have been randomized.
Time frame: At Week 4
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4
Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\>40mmHg and \<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups. To evaluate the difference in change, least squares mean change value is reported.
Time frame: Randomization to Week 4
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
Difference in change in trough home SBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication.
Time frame: Randomization to Week 4
Difference in Change in Trough Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4
Difference in change in trough home DBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication. To evaluate the difference in change, least squares mean change value is reported.
Time frame: Randomization to Week 4
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 4
The percentage of participants achieving home seated mean SBP \<135 and DBP \<85 mmHg at Week 4 was evaluated
Time frame: At Week 4
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4
The percentage of participants achieving averaged home seated mean SBP \<130 and DBP \<80 mmHg at Week 4 was evaluated
Time frame: Randomization to Week 4
Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE) or a Serious Adverse Event (SAE) From Randomization to Week 4
The primary safety outcome is percentage of participants discontinued trial medication due to an Adverse Event (AE) or a Serious Adverse Event (SAE) from randomization to Week 4.
Time frame: Randomization to Week 4
Percentage of Participants With an Serious Adverse Event (SAE) From Randomization to Week 4
The secondary outcome is percentage of participants with an SAE from randomization to Week 4
Time frame: Randomization to Week 4
Percentage of Participants With Symptomatic Hypotension From Randomization to Week 4
The Secondary Safety Outcome is percentage of participants with symptomatic hypotension from randomization to Week 4
Time frame: Randomization to Week 4
Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 4
The Secondary safety outcome is percentage of participants with serum sodium concentration below 135 mmol/l at Week 4
Time frame: At Week 4
Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 4
The Secondary safety outcome is percentage of participants with serum sodium concentration above 145 mmol/l at Week 4
Time frame: At Week 4
The Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 4
The secondary safety outcome is percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 4
Time frame: At Week 4
Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 4
The secondary safety outcome is percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 4.
Time frame: At Week 4
Percentage of Participants With eGFR Drop of Over 30% From Randomization to Week 4
The secondary safety outcome is percentage of participants with eGFR drop of over 30% from randomization to Week 4
Time frame: Randomization to Week 4
Percentage of Participants With Serum Sodium <135mmol/l or >145 mmol/l, and/or Serum Potassium <3.5 mmol/l or >5.5mmol/l at Week 4
The secondary safety outcome is percentage of participants with serum sodium \<135mmol/l or \>145 mmol/l, and/or serum potassium \<3.5 mmol/l or \>5.5mmol/l at Week 4
Time frame: At Week 4
Percentage of Participants With Postural Hypotension at Week 4
The secondary safety outcome percentage of participants with postural hypotension at Week 4
Time frame: At Week 4
Percentage of Participants With Postural Hypertension at Week 4
The secondary safety outcome is percentage of participants with postural hypertension at Week 4
Time frame: At Week 4
The trial was conducted at 47 trial centers spread across 5 countries (United States of America \[USA\] 23, Great Britain 10, Sri Lanka 7, Australia 5, and Nigeria 2).
| Milestone | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Started | 0 | 0 | 755 |
| Completed | 0 | 0 | 295 |
| Not completed | 0 | 0 | 460 |
| Milestone | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Started | 113 | 119 | 63 |
| Completed | 91 | 91 | 50 |
| Not completed | 22 | 28 | 13 |
| Withdrew: Run in failure | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 2 |
| Withdrew: Participant moved to open-label extension (ole) study | 21 | 21 | 8 |
| Withdrew: Other | 0 | 2 | 0 |
| Withdrew: Missing | 0 | 1 | 0 |
Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\>60 mmHg and \<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.
| mmHg | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4 | -9.6 ± 1.00 | -10.4 ± 1.33 | -2.2 ± 1.16 |
Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\>60 mmHg and \<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.
| mmHg | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Difference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4 | -6.6 ± 0.94 | -8.2 ± 1.25 | 1.3 ± 1.19 |
Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\>40mmHg and \<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.
| mmHg | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4 | -3.5 ± 0.60 | -4.3 ± 0.93 | 0.5 ± 0.91 |
The percentage of participants achieving averaged clinic SBP \<140 and DBP \<90 mmHg at Week 4 was evaluated.
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4 | 73 | 83 | 23 |
The percentage of participants achieving averaged clinic SBP \<130 and DBP \<80 mmHg at Week 4 was evaluated. Participants were analyzed in the treatment group to which they have been randomized.
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4 | 23 | 36 | 2 |
Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\>40mmHg and \<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups. To evaluate the difference in change, least squares mean change value is reported.
| mmHg | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4 | -5.1 ± 0.76 | -6.6 ± 0.60 | -1.1 ± 0.79 |
Difference in change in trough home SBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication.
| mmHg | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4 | -8.1 ± 1.24 | -10.1 ± 1.36 | -1.3 ± 1.24 |
Difference in change in trough home DBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication. To evaluate the difference in change, least squares mean change value is reported.
| mmHg | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Difference in Change in Trough Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4 | -4.2 ± 0.83 | -5.7 ± 0.65 | -0.3 ± 0.93 |
The percentage of participants achieving home seated mean SBP \<135 and DBP \<85 mmHg at Week 4 was evaluated
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 4 | 67 | 64 | 15 |
The percentage of participants achieving averaged home seated mean SBP \<130 and DBP \<80 mmHg at Week 4 was evaluated
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4 | 32 | 40 | 7 |
The primary safety outcome is percentage of participants discontinued trial medication due to an Adverse Event (AE) or a Serious Adverse Event (SAE) from randomization to Week 4.
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants Discontinued Trial Medication Due to Adverse Event (AE) or a Serious Adverse Event (SAE) From Randomization to Week 4 | 0 | 6 | 1 |
The secondary outcome is percentage of participants with an SAE from randomization to Week 4
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With an Serious Adverse Event (SAE) From Randomization to Week 4 | 0 | 2 | 2 |
The Secondary Safety Outcome is percentage of participants with symptomatic hypotension from randomization to Week 4
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Symptomatic Hypotension From Randomization to Week 4 | 4 | 6 | 0 |
The Secondary safety outcome is percentage of participants with serum sodium concentration below 135 mmol/l at Week 4
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Serum Sodium Concentration Below 135 mmol/l at Week 4 | 4 | 1 | 0 |
The Secondary safety outcome is percentage of participants with serum sodium concentration above 145 mmol/l at Week 4
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Serum Sodium Concentration Above 145 mmol/l at Week 4 | 4 | 5 | 3 |
The secondary safety outcome is percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 4
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| The Percentage of Participants With Serum Potassium Concentration Below 3.5 mmol/l at Week 4 | 4 | 6 | 1 |
The secondary safety outcome is percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 4.
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Serum Potassium Concentration Above 5.5 mmol/l at Week 4 | 1 | 0 | 0 |
The secondary safety outcome is percentage of participants with eGFR drop of over 30% from randomization to Week 4
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With eGFR Drop of Over 30% From Randomization to Week 4 | 0 | 0 | 1 |
The secondary safety outcome is percentage of participants with serum sodium \<135mmol/l or \>145 mmol/l, and/or serum potassium \<3.5 mmol/l or \>5.5mmol/l at Week 4
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Serum Sodium <135mmol/l or >145 mmol/l, and/or Serum Potassium <3.5 mmol/l or >5.5mmol/l at Week 4 | 12 | 12 | 4 |
The secondary safety outcome percentage of participants with postural hypotension at Week 4
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Postural Hypotension at Week 4 | 7 | 4 | 3 |
The secondary safety outcome is percentage of participants with postural hypertension at Week 4
| Participants | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo |
|---|---|---|---|
| Percentage of Participants With Postural Hypertension at Week 4 | 19 | 31 | 13 |
Collected over 6 weeks (Single-blind placebo run-in period of 2 weeks and double-blind period of 4 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triple ¼ (GMRx2) | 0/113 (0%) | 0/113 (0%) | 25/113 (22.1%) |
| Triple ½ (GMRx2) | 0/119 (0%) | 3/119 (2.5%) | 32/119 (26.9%) |
| Placebo | 0/63 (0%) | 2/63 (3.2%) | 10/63 (15.9%) |
| Not Randomized | 0/460 (0%) | 2/460 (0.4%) | 17/460 (3.7%) |
| Event | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Not Randomized |
|---|---|---|---|---|
| COVID-19Infections and infestations | 0/113 | 2/119 | 2/63 | 0/460 |
| Cerebrovascular accidentNervous system disorders | 0/113 | 1/119 | 0/63 | 0/460 |
| ArteritisVascular disorders | 0/113 | 0/119 | 0/63 | 1/460 |
| HypertensionVascular disorders | 0/113 | 0/119 | 0/63 | 1/460 |
| Event | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Not Randomized |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/113 | 2/119 | 5/63 | 2/460 |
| Blood uric acid increasedInvestigations | 2/113 | 5/119 | 1/63 | 0/460 |
| DizzinessNervous system disorders | 0/113 | 3/119 | 0/63 | 2/460 |
| DyslipidaemiaMetabolism and nutrition disorders | 2/113 | 0/119 | 0/63 | 0/460 |
| Blood potassium decreasedInvestigations | 2/113 | 0/119 | 1/63 | 0/460 |
| Blood sodium increasedInvestigations | 0/113 | 2/119 | 1/63 | 0/460 |
| HypokalaemiaMetabolism and nutrition disorders | 0/113 | 2/119 | 0/63 | 0/460 |
| Blood cholesterol increasedInvestigations | 0/113 | 2/119 | 1/63 | 0/460 |
| Blood glucose increasedInvestigations | 0/113 | 2/119 | 0/63 | 0/460 |
| Glomerular filtration rate decreasedInvestigations | 0/113 | 2/119 | 0/63 | 0/460 |
Baseline characteristics were summarized on the safety population by randomized treatment groups
| Age, Continuous(years) | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Total |
|---|---|---|---|---|
| Mean | 49.5 ± 12.25 | 51.2 ± 9.88 | 50.9 ± 12.81 | 50.5 ± 11.47 |
| Sex: Female, Male(Participants) | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Total |
|---|---|---|---|---|
| Female | 68 | 61 | 36 | 165 |
| Male | 45 | 58 | 27 | 130 |
| Ethnicity (NIH/OMB)(Participants) | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 40 | 42 | 23 | 105 |
| Not Hispanic or Latino | 70 | 76 | 38 | 184 |
| Unknown or Not Reported | 3 | 1 | 2 | 6 |
| Race (NIH/OMB)(Participants) | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 1 | 3 |
| Asian | 26 | 27 | 8 | 61 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 18 | 20 | 11 | 49 |
| White | 66 | 72 | 43 | 181 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Total |
|---|---|---|---|---|
| United States | 59 | 65 | 33 | 157 |
| Sri Lanka | 19 | 18 | 6 | 43 |
| United Kingdom | 18 | 15 | 10 | 43 |
| Australia | 15 | 16 | 11 | 42 |
| Nigeria | 2 | 5 | 3 | 10 |
| Height(cm) | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Total |
|---|---|---|---|---|
| Mean | 165.97 ± 10.439 | 166.68 ± 10.247 | 167.36 ± 9.878 | 166.55 ± 10.223 |
| Weight(kg) | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Total |
|---|---|---|---|---|
| Mean | 85.50 ± 20.865 | 85.12 ± 22.419 | 84.92 ± 20.299 | 85.22 ± 21.319 |
| BMI(kg/m^2) | Triple ¼ (GMRx2) | Triple ½ (GMRx2) | Placebo | Total |
|---|---|---|---|---|
| Mean | 30.9 ± 6.04 | 30.4 ± 6.69 | 30.0 ± 5.67 | 30.5 ± 6.22 |
11 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — No If the sponsor receives a request for study data, then such requests will be reviewed by sponsor following completion of regulatory submissions and review, and with support from members of the GMRX2 steering committee who will advise on the scientific merit and integrity of the proposed analysis.
Ran from Jun 2021 to primary completion in Sep 2023, 27 months.
Results were first posted in Jun 2025, 1 year 8 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 27 months is above that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Telmisartan
George Medicines PTY Limited